Prostate cancer’s day in the sunBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a1249 (Published 11 August 2008) Cite this as: BMJ 2008;337:a1249
- Gerhardt Attard, clinical research fellow1,
- Alison H Reid, clinical research fellow1,
- David Dearnaley, consultant clinical oncologist1,
- Johann S De Bono, consultant medical oncologist1
- 1Institute for Cancer Research, Royal Marsden NHS Foundation Trust, Sutton SM2 5PT
Recently we and others have studied different anti-cancer drugs in patients with castration resistant prostate cancer (CRPC), including HER2 targeting drugs, pan-ErbB inhibitors, histone deacetylase inhibitors, anti-angiogenics, a survivin antisense, and several new cytotoxics.1 2 In none of these trials have we observed anything like the biochemical, radiological, and, importantly, symptomatic benefit reported with abiraterone acetate.
The results of our phase I study have been confirmed by a second phase I study in North America and four phase II studies run by …